We are live on ! Find out more
CSBR icon

Champions Oncology
CSBR

14 hedge funds and large institutions have $16.2M invested in Champions Oncology in 2017 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

5% more capital invested

Capital invested by funds: $15.3M → $16.2M (+$818K)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0.13% less ownership

Funds ownership: 38.01% → 37.88% (-0.13%)

18% less funds holding

Funds holding: 17 → 14 (-3)

33% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 3

60% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 5

Holders
14
Holders Change
-3
Holders Change %
-17.65%
% of All Funds
0.32%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
2
Increased
2
Reduced
3
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$75.5K
2
Renaissance Technologies
Renaissance Technologies
New York
+$50.2K
3
Wells Fargo
Wells Fargo
California
+$16.7K
4
TRCT
Tower Research Capital (TRC)
New York
+$9.03K

Top Sellers

Rank Fund Capital Flow
1
SIM
Spark Investment Management
New York
-$82K
2
Commonwealth Equity Services
Commonwealth Equity Services
Massachusetts
-$62K
3
Millennium Management
Millennium Management
New York
-$28K
4
JP Morgan Chase
JP Morgan Chase
New York
-$10K
5
Deutsche Bank
Deutsche Bank
Germany
-$10K
Name Holding Trade Value Shares
Change 		Change in
Stake
BPI
1
Battery Partners IX
Massachusetts
$7.58M – – –
NMC
2
NEA Management Company
Maryland
$6.06M – – –
PA
3
Perceptive Advisors
New York
$1.5M – – –
Vanguard Group
4
Vanguard Group
Pennsylvania
$423K +$75.5K +21,169 +24%
Renaissance Technologies
5
Renaissance Technologies
New York
$241K +$50.2K +14,095 +29%
SKK
6
Shepherd Kaplan Krochuk
Massachusetts
$150K -$8.91K -2,500 -6%
Deutsche Bank
7
Deutsche Bank
Germany
$59K -$10K -2,805 -15%
Millennium Management
8
Millennium Management
New York
$55K -$28K -7,853 -36%
SSB
9
Sandy Spring Bank
Maryland
$32K – – –
Wells Fargo
10
Wells Fargo
California
$18K +$16.7K +4,697 New
Morgan Stanley
11
Morgan Stanley
New York
$14K – – –
TRCT
12
Tower Research Capital (TRC)
New York
$10K +$9.03K +2,533 New
VIMU
13
Veritas Investment Management (UK)
United Kingdom
$8K – – –
SIM
14
Spark Investment Management
New York
– -$82K -22,598 Closed
Commonwealth Equity Services
15
Commonwealth Equity Services
Massachusetts
– -$62K -16,767 Closed
JP Morgan Chase
16
JP Morgan Chase
New York
– -$10K -2,500 Closed
Acadian Asset Management
17
Acadian Asset Management
Massachusetts
– -$4K -978 Closed
Bank of America
18
Bank of America
North Carolina
– -$1K -277 Closed

CSBR Hedge Fund Activity: Q4 2017 in Review

14 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Champions Oncology (CSBR) for Q4 2017, worth a combined $16.2M — up 5.3% from $15.3M a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of CSBR and 2 opened new positions — a net loss of 3 holders — while 3 trimmed existing stakes and 2 added.

The largest buyer was Vanguard Group, adding an estimated $75.5K. The largest seller was Spark Investment Management, exiting entirely with an estimated $82K sold.

  • 14 institutional investors held Champions Oncology (CSBR) as of Q4 2017, down from 17 in Q3 2017.
  • Funds reported $16.2M of Champions Oncology stock for Q4 2017, up 5.3% quarter-over-quarter.
  • 2 funds opened new Champions Oncology positions in Q4 2017 and 5 closed out, a net change of -3 holders.
  • The largest Champions Oncology buyer in Q4 2017 was Vanguard Group, an estimated $75.5K added.
  • The largest Champions Oncology seller in Q4 2017 was Spark Investment Management, an estimated $82K sold.

Based on aggregated 13F filings for Q4 2017.